Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611659 | 0.90 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL29475007 | 0.90 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL318036 | 0.90 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL28892033 | 0.87 | CA2 (0.47) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL19145278 | 0.84 | CA2 (0.61) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL7956494 | 0.82 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL4336643 | 0.82 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL4336649 | 0.82 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL8073013 | 0.82 | CA2 (0.59) | CA2ATMKDM4EALDH1A1PPARG | |
| SCHEMBL291363 | 0.81 | CA2 (0.68) | CA2ATMKDM4EALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20220009957-A1 | Methods for Preparing Bile Acids | MEDYTOX INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| EP-3114112-B1 | CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL | ALPHORA RES INC (CA) | 2021-12-15 | — | — | EP | disclosed |
| US-11161872-B2 | Methods for preparing bile acids | MEDYTOX INC. (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20200369712-A1 | METHODS FOR PREPARING BILE ACIDS | WUXI APPTEC (SHANGHAI) CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| US-10301274-B2 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | SANDOZ AG (CH) | 2019-05-28 | — | — | US | disclosed |
| EP-3004036-B1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LTD (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| EP-3004036-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | Leo Laboratories Limited (IE) | 2016-04-13 | — | — | EP | disclosed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | disclosed |
| WO-2015131286-A1 | CRYSTALLINE DERIVATIVES OF (S)-1-((2R,3R,4S,5S)-5-ALLYL-3-METHOXY-4-(TOSYLMETHYL)TETRAHYDROFURAN-2-YL)-3-AMINOPROPAN-2-OL | ALPHORA RESEARCH INC. (CA) | 2015-09-11 | — | — | WO | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301274-B2 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-YL)-3-aminopropan-2-ol | ERLIN1, ERLIN2, MAN1B1 | CA2 3906/4885ATM 1895/4885KDM4E 3278/4885 |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | CA2 1415/4885ATM 2801/4885KDM4E 3559/4885 |
| US-20220009957-A1 | Methods for Preparing Bile Acids | DHCR7, CYP46A1, CYP27A1 | CA2 2601/4885ATM 2813/4885KDM4E 4488/4885 |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | CYP51A1, ERG28, UTP20 | CA2 1131/4885ATM 2399/4885KDM4E 2549/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | CA2 1415/4885ATM 2801/4885KDM4E 3559/4885 |
| US-20200369712-A1 | METHODS FOR PREPARING BILE ACIDS | DHCR7, CYP46A1, CYP27A1 | CA2 2601/4885ATM 2813/4885KDM4E 4488/4885 |
| US-11161872-B2 | Methods for preparing bile acids | DHCR7, CYP46A1, CYP27A1 | CA2 2601/4885ATM 2813/4885KDM4E 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.